Phase 1 Brain Cancer Trial, Recruiting NCT06650163 Sponsor: Jonsson Comprehensive Cancer Center Condition: Brain Cancer
Back to Brain Cancer

Phase 1 Brain Cancer Trial, Recruiting

NCT06650163
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 or older
  • People who have been diagnosed with a brain tumor, including brain metastases (cancer that has spread to the brain), any grade of glioma, or meningioma
  • People who are already scheduled to have standard surgical removal of their brain tumor as part of their normal medical care
  • People who are willing and able to give written consent to take part (or have a legal representative who can do so on their behalf)

Who may not be able to join:

  • People under 18 years of age
  • People who have a condition or health issue that, in the investigator's judgment, could put their safety at risk or affect the quality of the trial data
  • People who have not been medically cleared to have surgery
  • People who are unable to tolerate an MRI scan or a PET/CT scan
  • Women who are pregnant or breastfeeding
  • People whose kidney function test results fall outside acceptable levels set by the trial (confirm with trial site)
  • People whose liver function test results — including bilirubin levels — fall outside acceptable levels set by the trial (confirm with trial site)
  • People whose liver enzyme levels (AST and ALT) fall outside acceptable levels set by the trial, unless they have Gilbert's syndrome, in which case a higher threshold may apply (confirm with trial site)
  • People whose albumin (a protein measured in the blood) level is below 2.5 mg/dL
  • People who have a spleen that does not function properly, or who have had their spleen removed
  • People who have any condition that would make it unsafe to receive gadolinium-based contrast agent (a dye used during MRI scans)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Robert M Prins, UCLA / Jonsson Comprehensive Cancer Center

Phone: 310-592-9091

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Jonsson Comprehensive Cancer Center
Registry
ClinicalTrials.gov
Start date
5 December 2024
Est. completion
31 January 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Incidence of adverse events; Zirconium (Zr)-89 crefmirlimab berdoxam uptake

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov